Paul Lesueur
YOU?
Author Swipe
View article: EFFICIENCY AND TOXICITY OF OLAPARIB ARE STUDIED IN COMBINATION WITH RADIOTHERAPY IN CLINICAL AND PRECLINICAL MODELS
EFFICIENCY AND TOXICITY OF OLAPARIB ARE STUDIED IN COMBINATION WITH RADIOTHERAPY IN CLINICAL AND PRECLINICAL MODELS Open
View article: RADT-31. HYPO-FRACTIONATED STEREOTACTIC RE-IRRADIATION (HFSRT) PLUS DURVALUMAB VS HFSRT RE-IRRADIATION ALONE FOR PATIENTS WITH A RECURRENT GLIOBLASTOMA: RESULTS OF THE COMPARATIVE RANDOMIZED PHASE II STERIMGLI TRIAL
RADT-31. HYPO-FRACTIONATED STEREOTACTIC RE-IRRADIATION (HFSRT) PLUS DURVALUMAB VS HFSRT RE-IRRADIATION ALONE FOR PATIENTS WITH A RECURRENT GLIOBLASTOMA: RESULTS OF THE COMPARATIVE RANDOMIZED PHASE II STERIMGLI TRIAL Open
BACKGROUND Hypo-fractionated stereotactic radiotherapy (HFSRT) may enhance anti-PDL1 immunotherapy efficacy in recurrent glioblastoma by promoting immunogenic cell death. After establishing the safety of HFSRT combined with Durvalumab in a…
View article: Prospectively assessed hypothalamic-pituitary dysfunction after proton therapy in adults with head and neck, skull base and brain tumors
Prospectively assessed hypothalamic-pituitary dysfunction after proton therapy in adults with head and neck, skull base and brain tumors Open
View article: Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study
Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study Open
View article: Particle Therapy to Overcome Cancer Radiation Resistance: “ARCHADE” Consortium Updates in Radiation Biology
Particle Therapy to Overcome Cancer Radiation Resistance: “ARCHADE” Consortium Updates in Radiation Biology Open
Radiation therapy is a medical treatment that uses high doses of radiation to kill or damage cancer cells. It works by damaging the DNA within the cancer cells, ultimately causing cell death. Radiotherapy can be used as a primary treatment…
View article: Correction: Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG)
Correction: Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG) Open
International audience
View article: Supplementary Figure 1a. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
Supplementary Figure 1a. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study Open
A. Progression-free (left) and overall (right) survival among the 30 patients enrolled in the two sequential olaparib dose-escalations of the trial.
View article: Supplementary Figure 1c. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
Supplementary Figure 1c. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study Open
C. Progression-free (left) and overall (right) survival for first and second olaparib dose-escalation cohorts of the trial. Progression-free survival was defined as the time elapsed from treatment start to RANO progression or death from an…
View article: Supplementary Table 1 from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
Supplementary Table 1 from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study Open
Representativeness of Study Participants
View article: Data from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
Data from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study Open
Purpose:Radiochemotherapy remains the mainstay of glioblastoma (GBM) first-line treatment after extended surgery, but the prognosis is still poor. PARP inhibitors like olaparib may improve GBM outcomes. We implemented a phase I to IIa tria…
View article: Supplementary Figure 2. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
Supplementary Figure 2. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study Open
Magnetic Resonance Imaging (gadolinium, FLAIR and perfusion sequences from left to right) at baseline (top) and 60 months (bottom) after start of treatment in first line treatment of a partially resected glioblastoma patient.
View article: Supplementary Figure 1b. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
Supplementary Figure 1b. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study Open
B. Progression-free (left) and overall (right) survival according to MGMT status among the patients enrolled in the two sequential olaparib dose-escalations of the trial.
View article: Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG)
Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG) Open
View article: Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01)
Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01) Open
View article: Proton therapy for adult-type diffuse glioma: A systematic review
Proton therapy for adult-type diffuse glioma: A systematic review Open
View article: Prospective Assessment of Hypothalamic-Pituitary Deficiencies in Patients with a Heavily Radiation Exposed Pituitary Gland
Prospective Assessment of Hypothalamic-Pituitary Deficiencies in Patients with a Heavily Radiation Exposed Pituitary Gland Open
View article: Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR) Open
View article: Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions Open
Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can b…
View article: Impact of Covid-19 pandemic on neuro-oncology multidisciplinary tumor board in the pre-vaccine era: the Normandy experience
Impact of Covid-19 pandemic on neuro-oncology multidisciplinary tumor board in the pre-vaccine era: the Normandy experience Open
View article: Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study
Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study Open
Objective: To evaluate the incidence of the abscopal response (AR) in patients with metastatic melanoma requiring palliative radiotherapy (RT). Patients and methods: Patients treated for metastatic melanoma between January 1998 and Februar…
View article: Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study Open
The optimal consolidation strategy for primary central nervous system lymphoma (PCNSL) remains controversial. Preventing radio-induced neurotoxicity of consolidation treatment through reduced-dose whole-brain radiotherapy (rdWBRT) at a dos…
View article: How can we consider variable RBE and LETd prediction during clinical practice? A pediatric case report at the Normandy Proton Therapy Centre using an independent dose engine
How can we consider variable RBE and LETd prediction during clinical practice? A pediatric case report at the Normandy Proton Therapy Centre using an independent dose engine Open
View article: Nouvelles indications de protonthérapie et essais cliniques en cours : tumeurs intracrâniennes
Nouvelles indications de protonthérapie et essais cliniques en cours : tumeurs intracrâniennes Open
View article: Prospective Assessment of Early Proton Therapy-Induced Optic Neuropathy in Patients With Intracranial, Orbital or Sinonasal Tumors: Impact of A Standardized Ophthalmological Follow Up
Prospective Assessment of Early Proton Therapy-Induced Optic Neuropathy in Patients With Intracranial, Orbital or Sinonasal Tumors: Impact of A Standardized Ophthalmological Follow Up Open
Purpose Proton therapy (PT) can be a good option to achieve tumor control while reducing the probability of radiation induced toxicities compared to X-ray-based radiotherapy. However, there are still uncertainties about the effects of PT o…
View article: Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer.
Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer. Open
e15501 Background: Concomitant radiochemotherapy is the standard treatment of locally advanced epidermoid anal canal carcinoma (EACC) but conventional radiotherapy (RT) frequently induces significant non-hematological toxicities, resulting…
View article: Adjuvant hypofractionated stereotactic radiotherapy after resection of single large brain metastasis in patients with oligo-metastatic disease: a strategy finally validated?
Adjuvant hypofractionated stereotactic radiotherapy after resection of single large brain metastasis in patients with oligo-metastatic disease: a strategy finally validated? Open
View article: Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial
Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial Open
View article: Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes
Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes Open
Introduction: Lacrymal cystic adenoid carcinoma is a rare disease for which optimal treatment is still debated. In fact, despite aggressive treatment such as eye sparing surgery or orbital exenteration, following by adjuvant radioth…
View article: Hadrontherapy Interactions in Molecular and Cellular Biology
Hadrontherapy Interactions in Molecular and Cellular Biology Open
The resistance of cancer cells to radiotherapy is a major issue in the curative treatment of cancer patients. This resistance can be intrinsic or acquired after irradiation and has various definitions, depending on the endpoint that is cho…
View article: P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting
P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting Open
BACKGROUND Optimal treatment strategy for newly diagnosed primary PCNSL remains controversial. The high risk of radio-induced late-delayed neurotoxicity in patients who achieve long-term disease control constrains the use of classical cons…